Exploiting the p53 pathway for cancer diagnosis and therapy

Hematology Journal

Volumn 4, Issue 4, 2003, Pages 233-247

  Woods, Yvonne L ^a   Lane, David P ^a  

^a UNIVERSITY OF DUNDEE   (United Kingdom)

Author keywords

Cancer; Mdm2; p14Arf; p53; Tumour therapy

Indexed keywords

4 (3 DIMETHYLAMINOPROPYLAMINO) 2 (4 METHOXYSTYRYL)QUINAZOLINE; 6 CYCLOHEXYLMETHOXY 2 (4 SULFAMOYLANILINO)PURINE; 6 O CYCLOHEXYLMETHYLGUANINE; ANTIMYCIN A1; ANTINEOPLASTIC AGENT; ARF PROTEIN; CISPLATIN; COMPLEMENTARY RNA; CYCLIN DEPENDENT KINASE; CYCLIN DEPENDENT KINASE INHIBITOR; CYCLINE; CYCLOPHOSPHAMIDE; EPIRUBICIN; FLAVAPIRIDOL; FLUOROURACIL; MITOGEN ACTIVATED PROTEIN KINASE; OLOMOUCIN; ONYX 015; ONYX 411; PACLITAXEL; PIFITHRIN ALPHA; PRIMA 1; PROTEIN BAX; PROTEIN BCL 2; PROTEIN BCL XL; PROTEIN MDM2; PROTEIN P53; ROSCOVITINE; ROSCOVOTINE; UNCLASSIFIED DRUG; UNINDEXED DRUG;

BIOCHEMISTRY; CANCER CELL; CANCER DIAGNOSIS; CANCER RESEARCH; CANCER RESISTANCE; CANCER THERAPY; CLINICAL PRACTICE; CLINICAL TRIAL; DISEASE COURSE; DRUG TARGETING; GENE THERAPY; GENOTOXICITY; HUMAN; LEUKEMIA; MOLECULAR GENETICS; NONHUMAN; REVIEW; TUMOR SUPPRESSOR GENE; VIRAL GENE DELIVERY SYSTEM; VIRAL GENE THERAPY;

APOPTOSIS; GENE THERAPY; HUMANS; NEOPLASMS; SIGNAL TRANSDUCTION; TUMOR SUPPRESSOR PROTEIN P53;

EID: 0043025622     PISSN: 14664860     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.thj.6200260     Document Type: Review

References (107)

1. Lain S. Protecting p53 from degradation. Biochem Soc Trans 2003; 31: 482-485.
2. Ted RH, David PL, Kathryn LB. Strategies for manipulating the p53 pathway in the treatment of human cancer. Biochem J 2000; 352: 1-17.
3. Donehower LA. The p53-deficient mouse: a model for basic and applied cancer studies. Semin Cancer Biol 1996; 7: 269-278.
4. Srivastava S, Zou ZQ, Pirollo K, Blattner W, Chang EH. Germ-line transmission of a mutated p53 gene in a cancer-prone family with Li-Fraumeni syndrome. Nature 1990; 348: 747-749.
5. Tyner SD, Venkatachalam S, Choi J, Jones S, Ghebranious N, Igelmann H et al. p53 mutant mice that display early ageing-associated phenotypes. Nature 2002; 415: 45-53.
6. Sharpless NE, DePinho RA. p53: good cop/bad cop. Cell 2002; 110: 9-12.
7. Zhao R, Gish K, Murphy M, Yin Y, Notterman D, Hoffman WH et al. Analysis of p53-regulated gene expression patterns using oligonucleotide arrays. Genes Dev 2000; 14: 981-993.
8. Levine AJ. p53, the cellular gatekeeper for growth and division. Cell 1997; 88: 323-331.
9. Montes de Oca LR, Wagner DS, Lozano G. Rescue of early embryonic lethality in mdm2-deficient mice by deletion of p53. Nature 1995; 378: 203-206.
10. Haupt Y, Maya R, Kazaz A, Oren M. Mdm2 promotes the rapid degradation of p53. Nature 1997; 387: 296-299.
11. Momand J, Zambetti GP, Olson DC, George D, Levine AJ. The mdm-2 oncogene product forms a complex with the p53 protein and inhibits p53-mediated transactivation. Cell 1992; 69: 1237-1245.
12. Catherine JT, James AG, Robert T. Repression of p53-mediated transcription by MDM2: a dual mechanism. Gen Dev 1997; 272: 21403-21407.
13. Vousden KH, Lu X. Live or let die: the cell's response to p53. Nat Rev Cancer 2002; 2: 594-604.
14. Lu ML, Wikman F, ORntoft TF, Charytonowicz E, Rabbani F, Zhang Z et al. Impact of alterations affecting the p53 pathway in bladder cancer on clinical outcome, assessed by conventional and array-based methods. Clin Cancer Res 2002; 8: 171-179.
15. Leone G, Voso MT, Sica S, Morosetti R, Pagano L. Therapy related leukemias: susceptibility, prevention and treatment. Leukemia Lymphoma 2001; 41: 255-276.
16. Olivier M, Eeles R, Hollstein M, Khan MA, Harris CC, Hainaut P. The IARC TP53 database: new online mutation analysis and recommendations to users. Hum Mutat 2002; 19: 607-614.
17. Hainaut P, Hollstein M. p53 and human cancer: the first ten thousand mutations. Adv Cancer Res 2000; 77: 81-137.
18. Midgley CA, Lane DP. p53 protein stability in tumour cells is not determined by mutation but is dependent on Mdm2 binding. Oncogene 1997; 15: 1179-1189.
19. de Vries A, Flores ER, Miranda B, Hsieh HM, van Oostrom CT, Sage J et al. Targeted point mutations of p53 lead to dominant-negative inhibition of wild-type p53 function. Proc Natl Acad Sci USA 2002; 99: 2948-2953.
20. Sigal A, Rotter V. Oncogenic mutations of the p53 tumor suppressor: the demons of the guardian of the genome. Cancer Res 2000; 60: 6788-6793.
21. Selivanova G, Kawasaki T, Ryabchenko L, Wiman KG. Reactivation of mutant p53: a new strategy for cancer therapy. Semin Cancer Biol 1998; 8: 369-378.
22. Foster BA, Coffey HA, Morin MJ, Rastinejad F. Pharmacological rescue of mutant p53 conformation and function. Science 1999; 286: 2507-2510.
23. Rippin TM, Bykov VJ, Freund SM, Selivanova G, Wiman KG, Fersht AR. Characterization of the p53-rescue drug CP-31398 in vitro and in living cells. Oncogene 2002; 21: 2119-2129.
24. Friedler A, Hansson LO, Veprintsev DB, Freund SM, Rippin TM, Nikolova PV et al. A peptide that binds and stabilizes p53 core domain: chaperone strategy for rescue of oncogenic mutants. Proc Natl Acad Sci USA 2002; 99: 937-942.
25. Bykov VJ, Issaeva N, Shilov A, Hultcrantz M, Pugacheva E, Chumakov P et al. Restoration of the tumor suppressor function to mutant p53 by a low-molecular-weight compound. Nat Med 2002; 8: 282-288.
26. Zheng H, You H, Zhou XZ, Murray SA, Uchida T, Wulf G et al. The prolyl isomerase Pin1 is a regulator of p53 in genotoxic response. Nature 2002; 419: 849-853.
27. Zacchi P, Gostissa M, Uchida T, Salvagno C, Avolio F, Volinia S et al. The prolyl isomerase Pin1 reveals a mechanism to control p53 functions after genotoxic insults. Nature 2002; 419: 853-857.
28. Sullenger BA, Gilboa E. Emerging clinical applications of RNA. Nature 2002; 418: 252-258.
29. Watanabe T, Sullenger BA. Induction of wild-type p53 activity in human cancer cells by ribozymes that repair mutant p53 transcripts. Proc Natl Acad Sci USA 2000; 97: 8490-8494.
30. Chen PL, Chen YM, Bookstein R, Lee WH. Genetic mechanisms of tumor suppression by the human p53 gene. Science 1990; 250: 1576-1580.
31. Merritt JA, Roth JA, Logothetis CJ. Clinical evaluation of adenoviral-mediated p53 gene transfer: review of INGN 201 studies. Semin Oncol 2001; 28: 105-114.
32. Xu L, Pirollo KF, Chang EH. Tumor-targeted p53-gene therapy enhances the efficacy of conventional chemo/radiotherapy. J Control Release 2001; 74: 115-128.
33. Pirollo KF, Hao Z, Rait A, Jang YJ, Fee Jr WE, Ryan P et al. p53 mediated sensitization of squamous cell carcinoma of the head and neck to radiotherapy. Oncogene 1997; 14: 1735-1746.
34. Roth JA, Grammer SF, Swisher SG, Komaki R, Nemunaitis J, Merritt J et al. Gene therapy approaches for the management of non-small cell lung cancer. Semin Oncol 2001; 28: 50-56.
35. Phelan A, Elliott G, O'Hare P. Intercellular delivery of functional p53 by the herpesvirus protein VP22. Nat Biotechnol 1998; 16: 440-443.
36. Zender L, Kuhnel F, Kock R, Manns M, Kubicka S. VP22-mediated intercellular transport of p53 in hepatoma cells in vitro and in vivo. Cancer Gene Ther 2002; 9: 489-496.
37. Zender L, Kock R, Eckhard M, Frericks B, Gosling T, Gebhardt T et al. Gene therapy by intrahepatic and intratumoral trafficking of p53-VP22 induces regression of liver tumors. Gastroenterology 2002; 123: 608-618.
38. Atencio IA, Avanzini JB, Johnson D, Neuteboom S, Vaillancourt MT, Nielsen, LL et al. Enhanced apoptotic activity of a p53 variant in tumors resistant to wild-type p53 treatment. Mol Ther 2001; 4: 5-12.
39. Nicklin SA, Baker AH. Tropism-modified adenoviral and adeno-associated viral vectors for gene therapy. Curr Gene Ther 2002; 2: 273-293.
40. Schatzlein AG. Non-viral vectors in cancer gene therapy: principles and progress. Anticancer Drugs 2001; 12: 275-304.
41. Xu L, Pirollo KF, Tang WH, Rait A, Chang E H. Transferrin-liposome-mediated systemic p53 gene therapy in combination with radiation results in regression of human head and neck cancer xenografts. Hum Gene Ther 1999; 10: 2941-2952.
42. Xu L, Frederik P, Pirollo KF, Tang WH, Rait A, Xiang LM et al. Self-assembly of a virus-mimicking nanostructure system for efficient tumor-targeted gene delivery. Hum Gene Ther 2002; 13: 469-481.
43. Xu L, Tang WH, Huang CC, Alexander W, Xiang LM, Pirollo KF et al. Systemic p53 gene therapy of cancer with immunolipoplexes targeted by anti-transferrin receptor scFv. Mol Med 2001; 7: 723-734.
44. Sausville EA, El Sayed Y, Monga M, Kim G. Signal transduction directed cancer treatments. Annu Rev Pharmacol Toxicol 2003; 43: 199-231.
45. McClue SJ, Blake D, Clarke R, Cowan A, Cummings L, Fischer PM et al. In vitro and in vivo antitumor properties of the cyclin dependent kinase inhibitor CYC202 (R-roscovitine). Int J Cancer 2002; 102: 463-468.
46. Ljungman M, Paulsen MT. The cyclin-dependent kinase inhibitor roscovitine inhibits RNA synthesis and triggers nuclear accumulation of p53 that is unmodified at Ser15 and Lys382. Mol Pharmacol 2001; 60: 785-789.
47. Arris CE, Boyle FT, Calvert AH, Curtin NJ, Endicott JA, Garman EF et al. Identification of novel purine and pyrimidine cyclin-dependent kinase inhibitors with distinct molecular interactions and tumor cell growth inhibition profiles. J Med Chem 2000; 43: 2797-2804.
48. Davies TG, Bentley J, Arris CE, Boyle FT, Curtin NJ, Endicott JA et al. Structure-based design of a potent purine-based cyclin-dependent kinase inhibitor. Nat Struct Biol 2002; 9: 745-749
49. Zheleva DI, McInnes C, Gavine AL, Zhelev NZ, Fischer PM, Lane DP. Highly potent p21WAF1-derived peptide inhibitors of CDK-mediated pRb phosphorylation: delineation and structural insight into their interactions with cyclin A. J Peptide Res 2002; 60: 257-270.
50. Bacus SS, Gudkov AV, Lowe M, Lyass L, Yung Y, Komarov AP et al. Taxol-induced apoptosis depends on MAP kinase pathways (ERK and p38) and is independent of p53. Oncogene 2001; 20: 147-155.
51. Bertheau P, Plassa F, Espie M, Turpin E, De Roquancourt A, Marty M et al. Effect of mutated TP53 on response of advanced breast cancers to high-dose chemotherapy. Lancet 2002; 360: 852-854.
52. Green DR, Evan GI. A matter of life and death. Cancer Cell 2002; 1: 19-30.
53. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell 2000; 10: 57-70.
54. Johnstone RW, Ruefli AA, Lowe SW. Apoptosis: a link between cancer genetics and chemotherapy. Cell 2002; 108: 153-164.
55. Seoane J, Le HV, Massague J. Myc suppression of the p21(Cip1) Cdk inhibitor influences the outcome of the p53 response to DNA damage. Nature 2002; 419: 729-734.
56. Cory S, Adams JM. The bcl2 family: regulators of the cellular life-or-death switch. Nat Rev Cancer 2002; 2: 647-656.
57. Bourdon JC, Renzing J, Robertson PL, Fernandes KN, Lane DP. Scotin, a novel p53-inducible proapoptotic protein located in the ER and the nuclear membrane. J Cell Biol 2002; 158: 235-246.
58. Miyashita T, Reed JC. Tumor suppressor p53 is a direct transcriptional activator of the human bax gene. Cell 1995; 80: 293-299.
59. Oda E, Ohki R, Murasawa H, Nemoto J, Shibue T, Yamashita T et al. Noxa, a BH3-only member of the Bcl-2 family and candidate mediator of p53-induced apoptosis. Science 2000; 288: 1053-1058.
60. Nakano K, Vousden KH. PUMA, a novel proapoptotic, gene is induced by p53. Mol Cell 2001; 7: 683-694.
61. McCurrach ME, Connor TM, Knudson CM, Korsmeyer SJ, Lowe SW. bax-deficiency promotes drug resistance and oncogenic transformation by attenuating p53-dependent apoptosis. Proc Natl Acad Sci USA 1997; 94: 2345-2349.
62. Sattler M, Liang H, Nettesheim D, Meadows RP, Harlan JE, Eberstadt M et al. Structure of Bcl-xL-Bak peptide complex: recognition between regulators of apoptosis. Science 1997; 275: 983-986.
63. Wang JL, Liu D, Zhang ZJ, Shan S, Han X, Srinivasula SM et al. Structure-based discovery of an organic compound that binds Bcl-2 protein and induces apoptosis of tumor cells. Proc Natl Acad Sci USA 2000; 97: 7124-7129.
64. Degterev A, Lugovskoy A, Cardone M, Mulley B, Wagner G, Mitchison T et al. Identification of small-molecule inhibitors of interaction between the BH3 domain and Bcl-xL. Nat Cell Biol 2001; 3: 173-182.
65. Tzung SP, Kim KM, Basanez G, Giedt CD, Simon J, Zimmerberg J et al. Antimycin A mimics a cell-death-inducing Bcl-2 homology domain 3. Nat Cell Biol 2001; 3: 183-191.
66. Letai A, Bassik M, Walensky L, Sorcinelli M, Weiler S, Korsmeyer S. Distinct BH3 domains either sensitize or activate mitochondrial apoptosis, serving as prototype cancer therapeutics. Cancer Cell 2002; 2: 183-192.
67. Baell J, Huang D. Prospects for targeting the Bcl-2 family of proteins to develop novel cytotoxic drugs. Biochem Pharmacol 2002; 64: 851-863.
68. Soengas MS, Capodieci P, Polsky D, Mora J, Esteller M, Opitz-Araya X et al. Inactivation of the apoptosis effector Apaf-1 in malignant melanoma. Nature 2001; 409: 207-211.
69. Fantin VR, Berardi MJ, Scorrano L, Korsmeyer SJ, Leder P. A novel mitochondriotoxic small molecule that selectively inhibits tumor cell growth. Cancer Cell 2002; 2: 29-42.
70. Zhu J, Gao B, Zhao J, Balmain A. Targeting gene expression to tumor cells with loss of wild-type p53 function. Cancer Gene Ther 2000; 7: 4-12.
71. White E. Regulation of the cell cycle and apoptosis by the oncogenes of adenovirus. Oncogene 2001; 20: 7836-7846.
72. Bischoff JR, Kirn DH, Williams A, Heise C, Horn S, Muna M. An adenovirus mutant that replicates selectively in p53-deficient human tumor cells. Science 1996; 274: 373-376.
73. Lane DP. Killing tumor cells with viruses-a question of specificity. Nat Med 1998; 4: 1012-1013.
74. Khuri FR, Nemunaitis J, Ganly I, Arseneau J, Tannock IF, Romel L et al. A controlled trial of intratumoral ONYX-015, a selectively-replicating adenovirus, in combination with cisplatin and 5-fluorouracil in patients with recurrent head and neck cancer. Nat Med 2000; 6: 879-885.
75. Ramachandra M, Rahman A, Zou A, Vaillancourt M, Howe JA, Antelman D et al. Re-engineering adenovirus regulatory pathways to enhance oncolytic specificity and efficacy. Nat Biotechnol 2001; 19: 1035-1041.
76. Johnson L, Shen A, Boyle L, Kunich J, Pandey K, Lemmon M et al. Selectively replicating adenoviruses targeting deregulated E2F activity are potent, systemic antitumor agents. Cancer Cell 2002; 1: 325-337.
77. Komarov PG, Komarova EA, Kondratov RV, Christov-Tselkov K, Coon JS, Chernov MV. A chemical inhibitor of p53 that protects mice from the side effects of cancer therapy. Science 1999; 285: 1733-1737.
78. Thomas M, Pim D, Banks L. The role of the E6-p53 interaction in the molecular pathogenesis of HPV. Oncogene 1999; 18: 7690-7700.
79. Sherr C, McCormick F. The RB and p53 pathways in cancer. Cancer Cell 2002; 2: 103-112.
80. Hietanen S, Lain S, Krausz E, Blattner C, Lane DP. Activation of p53 in cervical carcinoma cells by small molecules. Proc Natl Acad Sci USA 2000; 97: 8501-8506.
81. Hannon GJ. RNA interference. Nature 2002; 418: 244-251.
82. Jiang M, Milner J. Selective silencing of viral gene expression in HPV-positive human cervical carcinoma cells treated with siRNA, a primer of RNA interference. Oncogene 2002; 21: 6041-6048.
83. Caspari T. How to activate p53. Curr Biol 2000; 10: R315-R317.
84. Gronbaek K, Worm J, Ralfkiaer E, Ahrenkiel V, Hokland P, Guldberg P. ATM mutations are associated with inactivation of the ARF-TP53 tumor suppressor pathway in diffuse large B-cell lymphoma. Blood 2002; 100: 1430-1437.
85. Takai H, Naka K, Okada Y, Watanabe M, Harada N, Saito S et al. Chk2-deficient mice exhibit radioresistance and defective p53-mediated transcription. EMBO J 2002; 21: 5195-5205.
86. Ingvarsson S, Sigbjornsdottir BI, Huiping C, Hafsteinsdottir SH, Ragnarsson G, Barkardottir RB et al. Mutation analysis of the CHK2 gene in breast carcinoma and other cancers. Breast Cancer Res 2002; 4: R4.
87. Freedman DA, Wu L, Levine AJ. Functions of the MDM2 oncoprotein. Cell Mol Life Sci 1999; 55: 96-107.
88. Wang H, Nan L, Yu D, Agrawal S, Zhang R. Antisense anti-MDM2 oligonucleotides as a novel therapeutic approach to human breast cancer: in vitro and in vivo activities and mechanisms. Clin Cancer Res 2001; 7: 3613-3624.
89. Wang H, Nan L, Yu D, Lindsey JR, Agrawal S, Zhang R. Anti-tumor efficacy of a novel antisense anti-MDM2 mixed-backbone oligonucleotide in human colon cancer models: p53-dependent and p53-independent mechanisms. Mol Med 2002; 8: 185-199.
90. Wang H, Zeng X, Oliver P, Le LP, Chen J, Chen L et al. MDM2 oncogene as a target for cancer therapy: An antisense approach. Int J Oncol 1999; 15: 653-660.
91. Lu W, Chen L, Peng Y, Chen J. Activation of p53 by roscovitine-mediated suppression of MDM2 expression. Oncogene 2001; 20: 3206-3216.
92. Blaydes JP, Gire V, Rowson JM, Wynford-Thomas D. Tolerance of high levels of wild-type p53 in transformed epithelial cells dependent on auto-regulation by mdm-2. Oncogene 1997; 14: 1859-1868.
93. Blaydes JP, Wynford-Thomas D. The proliferation of normal human fibroblasts is dependent upon negative regulation of p53 function by mdm2. Oncogene 1998; 16: 3317-3322.
94. Bottger V, Bottger A, Howard SF, Picksley SM, Chene P, Garcia-Echeverria C et al. Identification of novel mdm2 binding peptides by phage display. Oncogene 1996; 13: 2141-2147.
95. Bottger A, Bottger V, Sparks A, Liu WL, Howard SF, Lane DP. Design of a synthetic Mdm2-binding mini protein that activates the p53 response in vivo. Curr Biol 1997; 7: 860-869.
96. Chene P. Inhibiting the p53-MDM2 interaction: an important target for cancer therapy. Nat Rev Cancer 2003; 3: 102-109.
97. Sherr CJ. The INK4a/ARF network in tumour suppression. Nat Rev Mol Cell Biol 2001; 2: 731-737.
98. Brookes S, Rowe J, Ruas M, Llanos S, Clark PA, Lomax M et al. INK4a-deficient human diploid fibroblasts are resistant to RAS-induced senescence. EMBO J 2002; 21: 2936-2945.
99. Schmitt CA, McCurrach ME, de Stanchina E, Wallace-Brodeur RR, Lowe SW. INK4a/ARF mutations accelerate lymphomagenesis and promote chemoresistance by disabling p53. Genes Dev 1999; 13: 2670-2677.
100. Xirodimas D, Saville MK, Edling C, Lane DP, Lain S. Different effects of p14ARF on the levels of ubiquitinated p53 and Mdm2 in vivo. Oncogene 2001; 20: 4972-4983.
101. Xirodimas, DP, Stephen, CW, Lane DP. Cocompartmentalization of p53 and Mdm2 is a major determinant for Mdm2-mediated degradation of p53. Exp Cell Res 2001; 270: 66-77.
102. Midgley CA, Desterro JM, Saville MK, Howard S, Sparks A, Hay RT et al. An N-terminal p14ARF peptide blocks Mdm2-dependent ubiquitination in vitro and can activate p53 in vivo. Oncogene 2000; 19: 2312-2323.
103. Deng X, Kim M, Vandier D, Jung Y, Rikiyama T, Sgagias M et al. Recombinant adenovirus-mediated p14(ARF) overexpression sensitizes human breast cancer cells to cisplatin. Biochem Biophys Res Commun 2002; 296: 792-798.
104. Tango Y, Fujiwara T, Itoshima T, Takata Y, Katsuda K, Uno F et al. Adenovirus-Mediated p14ARF Gene Transfer Cooperates with Ad5CMV-p53 to Induce Apoptosis in Human Cancer Cells. Hum Gene Ther 2002; 13: 1373-1382.
105. Lai Z, Yang T, Kim YB, Sielecki TM, Diamond MA, Strack P et al. Differentiation of Hdm2-mediated p53 ubiquitination and Hdm2 autoubiquitination activity by small molecular weight inhibitors. Proc Natl Acad Sci USA 2002; 99: 14734-14739.
106. Druker BJ. Perspectives on the development of a molecularly targeted agent. Cancer Cell 2002; 1: 31-36.
107. Hahn WC, Weinberg RA. Modelling the molecular circuitry of cancer. Nat Rev Cancer 2002; 2: 331-341.